Szymkowiak Izabela, Marcinkowska Justyna, Kucinska Malgorzata, Regulski Milosz, Murias Marek
Curtis Health Caps S.A., Przezmierowo, Poland.
Department of Toxicology, Poznan University of Medical Sciences, Poznan, Poland.
Phytother Res. 2025 Jan;39(1):453-464. doi: 10.1002/ptr.8379. Epub 2024 Nov 18.
Annually, a growing body of studies substantiates the health advantages of polyphenolic compounds, yet their practical application is constrained by swift metabolism and low bioavailability. Resveratrol, a stilbene derivative showcasing typical polyphenolic traits, is particularly noteworthy. Despite abundant bioavailability data from in vitro and animal studies, applying these findings to humans demands nuanced consideration. The objective of this article is to conduct a meta-analysis on clinical trial data, systematically assessing the oral bioavailability of resveratrol and deriving meaningful insights into its efficacy in humans. To achieve this goal, we thoroughly examined publications across five major global databases: PubMed, Cochrane Library, Scopus, Embase, and Science Direct. The study exclusively included clinical trials involving healthy adults, where pharmacokinetic parameters were measured following the oral administration of at least one dose of resveratrol as a single preparation. For the meta-analysis data extraction, the mean score and standard deviation (SD) were included. Heterogeneity, degree of inconsistency between studies, and meta-regression were assessed. From these searches, we scrutinized data from 84 oral administrations encompassing nine resveratrol doses ranging from 25 to 5000 mg. Our findings indicate a linear increase in the amount of free resveratrol entering the bloodstream with the administered dose, while T values remain unaffected. The mean maximum plasma concentration of resveratrol (31.07 ng/mL) closely mirrors the mean C observed in the group administered a medium resveratrol dose ranging from 100 to 500 mg (33.59 ng/mL). This similarity implies the appropriateness of employing these specific doses of resveratrol, taking into consideration both its bioavailability and very low risk of potential side effects. However, the analysis of available human oral bioavailability data is constrained by methodological inconsistencies prevalent in existing studies. The meta-analysis underscores substantial heterogeneity, underscoring the imperative for multiple studies to rectify this prevailing trend.
每年,越来越多的研究证实了多酚类化合物对健康的益处,但其实际应用受到快速代谢和低生物利用度的限制。白藜芦醇是一种具有典型多酚特性的芪类衍生物,尤其值得关注。尽管体外和动物研究提供了丰富的生物利用度数据,但将这些发现应用于人类需要细致入微的考量。本文的目的是对临床试验数据进行荟萃分析,系统评估白藜芦醇的口服生物利用度,并深入了解其对人类的疗效。为实现这一目标,我们全面检索了全球五个主要数据库:PubMed、Cochrane图书馆、Scopus、Embase和Science Direct。该研究仅纳入了涉及健康成年人的临床试验,这些试验在口服至少一剂白藜芦醇单一制剂后测量了药代动力学参数。对于荟萃分析的数据提取,纳入了平均得分和标准差(SD)。评估了异质性、研究之间的不一致程度以及荟萃回归。通过这些检索,我们仔细审查了来自84次口服给药的数据,这些给药涵盖了9种白藜芦醇剂量,范围从25至5000毫克。我们的研究结果表明,随着给药剂量的增加,进入血液的游离白藜芦醇量呈线性增加,而T值不受影响。白藜芦醇的平均最大血浆浓度(31.07纳克/毫升)与接受100至500毫克中等白藜芦醇剂量组中观察到的平均C值(33.59纳克/毫升)非常接近。这种相似性意味着考虑到其生物利用度和潜在副作用的极低风险,采用这些特定剂量的白藜芦醇是合适的。然而,对现有人类口服生物利用度数据的分析受到现有研究中普遍存在的方法学不一致性的限制。荟萃分析强调了显著的异质性,突出了多项研究纠正这一普遍趋势的必要性。